- Home
- PFD vs RCEL Comparison
PFD vs RCEL Comparison
Compare PFD & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- RCEL
- Stock Information
- Founded
- PFD 1990
- RCEL N/A
- Country
- PFD United States
- RCEL United States
- Employees
- PFD N/A
- RCEL N/A
- Industry
- PFD Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- PFD Finance
- RCEL Health Care
- Exchange
- PFD Nasdaq
- RCEL Nasdaq
- Market Cap
- PFD 143.2M
- RCEL 140.5M
- IPO Year
- PFD N/A
- RCEL N/A
- Fundamental
- Price
- PFD $12.12
- RCEL $5.54
- Analyst Decision
- PFD
- RCEL Strong Buy
- Analyst Count
- PFD 0
- RCEL 4
- Target Price
- PFD N/A
- RCEL $13.75
- AVG Volume (30 Days)
- PFD 33.2K
- RCEL 1.3M
- Earning Date
- PFD 01-01-0001
- RCEL 11-06-2025
- Dividend Yield
- PFD 6.30%
- RCEL N/A
- EPS Growth
- PFD N/A
- RCEL N/A
- EPS
- PFD N/A
- RCEL N/A
- Revenue
- PFD N/A
- RCEL $74,884,000.00
- Revenue This Year
- PFD N/A
- RCEL $22.92
- Revenue Next Year
- PFD N/A
- RCEL $37.07
- P/E Ratio
- PFD N/A
- RCEL N/A
- Revenue Growth
- PFD N/A
- RCEL 38.32
- 52 Week Low
- PFD $8.53
- RCEL $3.60
- 52 Week High
- PFD $11.18
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- PFD 73.98
- RCEL 54.84
- Support Level
- PFD $11.94
- RCEL $5.03
- Resistance Level
- PFD $12.04
- RCEL $5.61
- Average True Range (ATR)
- PFD 0.08
- RCEL 0.39
- MACD
- PFD -0.01
- RCEL 0.00
- Stochastic Oscillator
- PFD 87.50
- RCEL 34.69
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.